ATE450256T1 - Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen - Google Patents
Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungenInfo
- Publication number
- ATE450256T1 ATE450256T1 AT07727719T AT07727719T ATE450256T1 AT E450256 T1 ATE450256 T1 AT E450256T1 AT 07727719 T AT07727719 T AT 07727719T AT 07727719 T AT07727719 T AT 07727719T AT E450256 T1 ATE450256 T1 AT E450256T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- receptor antagonists
- opioid receptor
- compositions containing
- kappa opioid
- Prior art date
Links
- 229940123257 Opioid receptor antagonist Drugs 0.000 title abstract 2
- 208000018459 dissociative disease Diseases 0.000 title abstract 2
- 102000048260 kappa Opioid Receptors Human genes 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108020001588 κ-opioid receptors Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006015733A DE102006015733A1 (de) | 2006-04-04 | 2006-04-04 | Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit |
| DE102006016991A DE102006016991A1 (de) | 2006-04-11 | 2006-04-11 | Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen |
| PCT/EP2007/053248 WO2007115975A2 (de) | 2006-04-04 | 2007-04-03 | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE450256T1 true ATE450256T1 (de) | 2009-12-15 |
Family
ID=38110094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07727719T ATE450256T1 (de) | 2006-04-04 | 2007-04-03 | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8063059B2 (https=) |
| EP (1) | EP2001456B1 (https=) |
| JP (1) | JP5128578B2 (https=) |
| AT (1) | ATE450256T1 (https=) |
| AU (1) | AU2007236003B2 (https=) |
| CA (1) | CA2646899C (https=) |
| CY (1) | CY1109862T1 (https=) |
| DE (1) | DE502007002185D1 (https=) |
| DK (1) | DK2001456T3 (https=) |
| EA (1) | EA014820B1 (https=) |
| ES (1) | ES2337622T3 (https=) |
| HR (1) | HRP20100113T1 (https=) |
| PL (1) | PL2001456T3 (https=) |
| PT (1) | PT2001456E (https=) |
| RS (1) | RS51211B (https=) |
| SI (1) | SI2001456T1 (https=) |
| WO (1) | WO2007115975A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5345637B2 (ja) | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
| ES2694352T3 (es) * | 2013-12-20 | 2018-12-20 | H. Lundbeck A/S | Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| LT3137081T (lt) | 2014-04-28 | 2018-02-26 | Orphomed, Inc. | Buprenorfino dimeras ir jo naudojimas gydant virškinamojo trakto sutrikimus |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170554A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028612A (en) * | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5780479A (en) * | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
| US6242456B1 (en) * | 1998-03-09 | 2001-06-05 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| EP1365756A2 (en) * | 2000-08-15 | 2003-12-03 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| JP2004518654A (ja) * | 2000-12-21 | 2004-06-24 | ザ マクレーン ホスピタル コーポレーション | 鬱病の治療法 |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| CA2521396A1 (en) * | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| JP2007526328A (ja) * | 2004-03-02 | 2007-09-13 | ファルマシア コーポレーション | 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物 |
| CN103087133B (zh) * | 2004-05-26 | 2016-09-14 | 伊诺泰克制药公司 | 嘌呤衍生物作为腺苷a1受体激动剂及其用法 |
| EP1750675B1 (en) * | 2004-06-02 | 2008-10-29 | Galephar M/F | Stable oral pharmaceutical compositions of buprenorphine and salt thereof |
-
2007
- 2007-04-03 JP JP2009503576A patent/JP5128578B2/ja not_active Expired - Fee Related
- 2007-04-03 US US12/296,125 patent/US8063059B2/en not_active Expired - Fee Related
- 2007-04-03 AT AT07727719T patent/ATE450256T1/de active
- 2007-04-03 ES ES07727719T patent/ES2337622T3/es active Active
- 2007-04-03 DE DE502007002185T patent/DE502007002185D1/de active Active
- 2007-04-03 PT PT07727719T patent/PT2001456E/pt unknown
- 2007-04-03 PL PL07727719T patent/PL2001456T3/pl unknown
- 2007-04-03 EA EA200802104A patent/EA014820B1/ru not_active IP Right Cessation
- 2007-04-03 CA CA2646899A patent/CA2646899C/en not_active Expired - Fee Related
- 2007-04-03 HR HR20100113T patent/HRP20100113T1/hr unknown
- 2007-04-03 WO PCT/EP2007/053248 patent/WO2007115975A2/de not_active Ceased
- 2007-04-03 DK DK07727719.2T patent/DK2001456T3/da active
- 2007-04-03 RS RSP-2010/0089A patent/RS51211B/sr unknown
- 2007-04-03 AU AU2007236003A patent/AU2007236003B2/en not_active Ceased
- 2007-04-03 EP EP07727719A patent/EP2001456B1/de active Active
- 2007-04-03 SI SI200730163T patent/SI2001456T1/sl unknown
-
2010
- 2010-02-25 CY CY20101100188T patent/CY1109862T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8063059B2 (en) | 2011-11-22 |
| ES2337622T3 (es) | 2010-04-27 |
| SI2001456T1 (sl) | 2010-04-30 |
| AU2007236003A1 (en) | 2007-10-18 |
| RS51211B (sr) | 2010-12-31 |
| HRP20100113T1 (hr) | 2010-04-30 |
| AU2007236003B2 (en) | 2012-10-18 |
| EA014820B1 (ru) | 2011-02-28 |
| EP2001456B1 (de) | 2009-12-02 |
| JP2009532434A (ja) | 2009-09-10 |
| DK2001456T3 (da) | 2010-04-12 |
| DE502007002185D1 (de) | 2010-01-14 |
| CA2646899A1 (en) | 2007-10-18 |
| US20090181999A1 (en) | 2009-07-16 |
| CY1109862T1 (el) | 2014-09-10 |
| WO2007115975A2 (de) | 2007-10-18 |
| CA2646899C (en) | 2014-05-06 |
| PL2001456T3 (pl) | 2010-05-31 |
| WO2007115975A3 (de) | 2008-02-14 |
| EA200802104A1 (ru) | 2009-04-28 |
| JP5128578B2 (ja) | 2013-01-23 |
| PT2001456E (pt) | 2010-03-03 |
| EP2001456A2 (de) | 2008-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201170624A1 (ru) | Изоникотинамидные антагонисты рецепторов орексинов | |
| DK2152690T3 (da) | Pyridylpiperidinorexin-receptorantagonister | |
| CY1110882T1 (el) | Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης | |
| CY1111927T1 (el) | Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων | |
| DE602005015577D1 (de) | Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden | |
| ATE450256T1 (de) | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| EA200900048A1 (ru) | Новые карбонилированные (аза)циклогексаны в качестве лигандов d3 рецептора дофамина | |
| EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
| DE602007006019D1 (de) | Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate | |
| UA92670C2 (ru) | Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе | |
| UA106873C2 (uk) | Сполуки заміщених діазепанів як антагоністи орексинових рецепторів | |
| TW200800958A (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
| EA201190017A1 (ru) | Аминоэфирные производные алкалоидов и их медицинские композиции | |
| MX2009003645A (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3. | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
| ATE542795T1 (de) | Benzylpiperazinderivate als motilin- rezeptorantagonisten | |
| ATE466841T1 (de) | 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden | |
| ATE505468T1 (de) | N-gebundene heterocyclische antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden | |
| ATE455111T1 (de) | Einen azepin-kern enthaltende antagonisten des histaminrezeptors | |
| MX2009000762A (es) | 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central. | |
| ATE541585T1 (de) | Antikörper gegen il-5-rezeptor zur verwendung in der behandlung von endometriose. | |
| HK1127349A (en) | 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of cns disorders |